Cancer Research Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06745323
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to learn more about tarlatamab in people with Small Cell Lung Cancer (SCLC; a type of fast-growing cancer that forms in tissues of the lung and can spread to other parts of...
-
A Randomized, Open-label Phase 3 Study of Amivantamab + mFOLFOX6 or FOLFIRI Versus Cetuximab + mFOLFOX6 or FOLFIRI as First-line Treatment in Participants with RAS/RAF Wild-Type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)
This study is currently enrolling.Associated Conditions: GastrointestinalResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapies. to...
-
NCT06014762
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find out if an investigational treatment called, P-CD19CD20-ALLO1, is safe and will help treat people with one of the following B cell malignancies: diffuse large B...
-
NCT06660654
A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research is to learn more about and investigational drug called raludotatug deruxtecan, hereafter referred to as D-DXd. it is being studies to see if it is effective, tolerable...
-
NCT05514717
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
This study is currently enrolling.Research Area: Clinical Cancer Research -
NCT06667076
A Phase 2, Open-Label, Multi-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-based Chemo as Second-line Treatment, in Participants with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchThe purpose of this study is to help researchers understand more about the possible effectiveness and safety of the combination of amivantamab and lazertinib in patients with non-small cell lung...
-
NCT06172478
A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is currently enrolling.Research Area: Clinical Cancer ResearchThe purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment”...
-
NCT05611931
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this Phase 3 study is to compare the PFS of patients receiving Selinexor maintenance therapy after prior systemic therapy to the PFS of patients receiving placebo as maintenance therapy...
-
NCT06619561
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05812807
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: BreastResearch Area: Clinical Cancer ResearchThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT05142696
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this part of the study is to evaluate safety of Lutathera in patients with extensive stage small cell lung cancer (ES-SCLC) and to find the recommended dose of Lutathera in combination...
-
NCT06760637
An Interventional, Open-label, Randomized, Multicenter Phase 3 Study of PF-07220060 plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants over 18 Years with Hormone Receptor (HR)-Positive, HER2-Negatrive Advanced/Metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced/Metastatic Disease
This study is currently enrolling.Associated Conditions: BreastResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of the study is to evaluate whether PF-07220060 plus letrozole can improve clinical outcomes relative to cyclin-dependent kinase (CDK) 4/6 inhibitor (CDK4/6i) (investigator’s choice...